Agios Pharmaceuticals posts $12.9 million third quarter PYRUKYND net revenues
Agios Pharmaceuticals Inc. reported $12.9 million in third quarter 2025 PYRUKYND net revenues. Selling, General and Administrative expenses were $41.3 million for the third quarter of 2025, an increase of $2.7 million compared to the same period in 2024, primarily attributed to investments in preparation for a potential U.S. commercial launch of PYRUKYND in thalassemia. The company held $1.3 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, compared to $1.5 billion at December 31, 2024. Agios stated that its current financial position, along with anticipated product revenue and interest income, is expected to support preparations for potential PYRUKYND commercial launches in thalassemia and sickle cell disease, as well as advancement of clinical programs and pipeline expansion. The PDUFA goal date for PYRUKYND's supplemental new drug application in thalassemia is set for December 7, 2025, with a European Commission decision expected by early 2026 following a positive CHMP opinion. Topline results from the RISE UP Phase 3 trial in sickle cell disease are anticipated by year-end, and a Phase 2b tebapivat trial in lower-risk MDS is fully enrolled, with topline results expected in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001439222-25-000114), on October 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.